Public Employees Retirement Association of Colorado Sells 4,144 Shares of Ironwood Pharmaceuticals (IRWD)

Public Employees Retirement Association of Colorado cut its stake in shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) by 14.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 24,883 shares of the biotechnology company’s stock after selling 4,144 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Ironwood Pharmaceuticals were worth $384,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in IRWD. Sarissa Capital Management LP acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $24,733,000. Senzar Asset Management LLC raised its position in shares of Ironwood Pharmaceuticals by 185.8% in the 4th quarter. Senzar Asset Management LLC now owns 1,448,800 shares of the biotechnology company’s stock valued at $21,718,000 after purchasing an additional 941,800 shares in the last quarter. Park West Asset Management LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $9,203,000. Broderick Brian C raised its position in shares of Ironwood Pharmaceuticals by 237.1% in the 4th quarter. Broderick Brian C now owns 487,065 shares of the biotechnology company’s stock valued at $7,301,000 after purchasing an additional 342,589 shares in the last quarter. Finally, State of Wisconsin Investment Board raised its position in shares of Ironwood Pharmaceuticals by 15.8% in the 4th quarter. State of Wisconsin Investment Board now owns 846,800 shares of the biotechnology company’s stock valued at $12,694,000 after purchasing an additional 115,800 shares in the last quarter.

In other news, CFO Gina Consylman sold 3,594 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $14.66, for a total value of $52,688.04. Following the completion of the sale, the chief financial officer now directly owns 59,125 shares in the company, valued at approximately $866,772.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 6,728 shares of company stock valued at $97,732 over the last quarter. Company insiders own 7.63% of the company’s stock.

Shares of Ironwood Pharmaceuticals opened at $18.08 on Monday, according to MarketBeat.com. Ironwood Pharmaceuticals has a twelve month low of $12.89 and a twelve month high of $19.94. The company has a quick ratio of 4.40, a current ratio of 4.42 and a debt-to-equity ratio of -21.52.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Tuesday, May 1st. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.06). Ironwood Pharmaceuticals had a negative net margin of 34.12% and a negative return on equity of 2,073.20%. The firm had revenue of $69.16 million during the quarter, compared to the consensus estimate of $78.65 million. During the same quarter last year, the firm posted ($0.33) earnings per share. Ironwood Pharmaceuticals’s revenue was up 32.6% compared to the same quarter last year. research analysts anticipate that Ironwood Pharmaceuticals will post -0.62 EPS for the current year.

A number of equities analysts have issued reports on the company. ValuEngine lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. Morgan Stanley lowered Ironwood Pharmaceuticals from an “equal” rating to a “weight” rating in a research report on Wednesday, May 9th. Barclays upped their target price on Ironwood Pharmaceuticals from $16.00 to $20.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 2nd. Mizuho raised Ironwood Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $16.00 to $24.00 in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals has an average rating of “Hold” and a consensus target price of $18.60.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply